@MarkFordem 14/07/2018 21:56The final analysis at 18 months of the 856 patient Phase II clinical study in early Alzheimer’s disease demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta accumulated in the brainFirst late-stage study data successfully demonstrating potential disease-modifying effects on both clinical function and amyloid beta accumulation in the brainNew data provide compelling evidence to further support amyloid hypothesis as a therapeutic target for Alzheimer’s diseaseEisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months Nasdaq:BIIB#1 de 1